NCT01913535 arm group 2e13939ac427dd3eea644d957c3ca810 [clinicaltrials_resource:NCT01913535/arm-group/2e13939ac427dd3eea644d957c3ca810]
arm group [clinicaltrials_vocabulary:arm-group]
NCT01913535 arm group 2e13939ac427dd3eea644d957c3ca810 [clinicaltrials_resource:NCT01913535/arm-group/2e13939ac427dd3eea644d957c3ca810]
Bio2RDF identifier
NCT01913535/arm-group/2e13939ac427dd3eea644d957c3ca810
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 13939ac427dd3eea644d957c3ca810
description [clinicaltrials_vocabulary:description]
Patients in this arm will rece ...... 3 subsequent days (in Phase 2)
identifier
clinicaltrials_resource:NCT01913535/arm-group/2e13939ac427dd3eea644d957c3ca810
title
NCT01913535 arm group 2e13939ac427dd3eea644d957c3ca810
@en
type
label
NCT01913535 arm group 2e13939a ...... 3939ac427dd3eea644d957c3ca810]
@en